Abstract:The pan‐cancer analyses of bromodomain containing 9 (BRD9) provided a comprehensive perspective for the development of BRD9‐based targeted therapies for a variety of different cancers. BRD9 may affect cancer progression through different phosphorylation sites or N6‐methyladenosine site modifications. BRD9 could be used as a novel biomarker for diagnosis of multiple cancer types. Our functional study of BRD9 showed interaction with SMARCD1. Knockdown of BRD9 could inhibit the progression of lung and colon cancers through the Wnt/β‐catenin signalling pathway. Background Mutations in one or more genes responsible for encoding subunits within the SWItch/Sucrose Non‐Fermentable (SWI/SNF) chromatin‐remodelling complexes are found in approximately 25% of cancer patients. Bromodomain containing 9 (BRD9) is a more recently identified protein coding gene, which can encode SWI/SNF chromatin‐remodelling complexes subunits. Although initial evaluations of the potential of BRD9‐based targeted therapy have been explored in the clinical application of a small number of cancer types, more detailed study of the diagnostic and prognostic potential, as well as the detailed biological mechanism of BRD9 remains unreported. Methods We used various bioinformatics tools to generate a comprehensive, pan‐cancer analyses of BRD9 expression in multiple disease types described in The Cancer Genome Atlas (TCGA). Experimental validation was conducted in tissue microarrays and cell lines derived from lung and colon cancers. Results Our study revealed that BRD9 exhibited elevated expression in a wide range of tumours. Analysis of survival data and DNA methylation for BRD9 indicated distinct conclusions for multiple tumours. mRNA splicing and molecular binding were involved in the functional mechanism of BRD9. BRD9 may affect cancer progression through different phosphorylation sites or N6‐methyladenosine site modifications. BRD9 could potentially serve as a novel biomarker for diagnosing different cancer types, especially could accurately forecast the prognosis of melanoma patients receiving anti‐programmed cell death 1 immunotherapy. BRD9 has the potential to serve as a therapeutic target, when pairing with etoposide in patients with melanoma. The BRD9/SMARCD1 axis exhibited promising discriminative performance in forecasting the prognosis of patients afflicted with liver hepatocellular carcinoma (LIHC) and mesothelioma. Additionally, this axis appears to potentially influence the immune response in LIHC by regulating the programmed death‐ligand 1 immune checkpoint. For experimental validation, high expression levels of BRD9 were observed in tumour tissue samples from both lung and colon cancer patients. Knocking down BRD9 led to the inhibition of lung and colon cancer development, likely via the Wnt/β‐catenin signalling pathway. Conclusions These pan‐cancer study revealed the diagnostic and prognostic potential, along with the biological mechanism of BRD9 as a novel therapeutic target in human tumours.

Targeting bromodomian-containing protein 8 (BRD8): An advanced tool to interrogate BRD8

The Therapeutic Potential of BRD4 in Cardiovascular Disease

Dual‐target inhibitors of bromodomain and extra‐terminal proteins in cancer: A review from medicinal chemistry perspectives

<b>Bromodomain and Extra-Terminal Domain Protein 2</b><b>in Multiple Human Diseases</b>

A Chemical Toolbox for the Study of Bromodomains and Epigenetic Signaling

Targeting Bromodomain and Extraterminal Proteins for Drug Discovery: From Current Progress to Technological Development

Bromodomain and Extraterminal Domain Protein 2 in Multiple Human Diseases.

Post-Translational Modifications of BRD4: Therapeutic Targets for Tumor

Pan‐cancer analyses of bromodomain containing 9 as a novel therapeutic target reveals its diagnostic, prognostic potential and biological mechanism in human tumours

Inhibition of BET bromodomains as a therapeutic strategy for cancer drug discovery.

PROTACs for BRDs Proteins in Cancer Therapy: a Review.

Chemical Proteomic Profiling of Bromodomains Enables the Wide-Spectrum Evaluation of Bromodomain Inhibitors in Living Cells.

Design, synthesis, and biological evaluation of BRD4 degrader

Recent Developments in Targeting Bromodomain and Extra Terminal Domain Proteins for Cancer Therapeutics

Discovery, X-ray Crystallography, and Anti-inflammatory Activity of Bromodomain-containing Protein 4 (BRD4) BD1 Inhibitors Targeting a Distinct New Binding Site

Selective inhibition of BET bromodomains

Targeting Bromodomain-Selective Inhibitors of BET Proteins in Drug Discovery and Development

Unveiling Allosteric Regulation and Binding Mechanism of BRD9 through Molecular Dynamics Simulations and Markov Modeling

BRD8 maintains glioblastoma by epigenetic reprogramming of the p53 network

Molecular mechanism study of several inhibitors binding to BRD9 bromodomain based on molecular simulations

Small-molecule BET Inhibitors in Clinical and Preclinical Development and Their Therapeutic Potential.